This article is more than 5 years old. Information may no longer be current.
Akorn signs deal for manufacture, supply of three generic glaucoma drugs
Click Here to Manage Email Alerts
BUFFALO GROVE, Ill. — Akorn has entered into an agreement with Switzerland-based Azad Pharma for Azad to develop and supply Akorn with generic versions of three glaucoma drugs, according to a press release from Akorn.
Akorn officials expect the drugs — generic equivalents versions of latanoprost, bimatoprost and travoprost — to be manufactured by South Korea-based Taejoon Pharmaceutical Co. Ltd. Both Azad and Taejoon will complete regulatory documents and, upon approval from the Food and Drug Administration, will manufacture and supply the drugs to Akorn.
Akorn will be responsible for regulatory filing of the abbreviated new drug applications and will own the applications. It will also have exclusive marketing and distribution rights to the drugs in the United States and Canada, according to the release. The company expects to launch and market the drugs based on their respective patent expiration dates, the release said.